Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| MYRIAD GENETICS INCMYGN · Entity 5953 | Director | December 05, 2019 | December 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,360 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 272 · Balance 78,360 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 83 |
Reported balance
Holding disclosure · report date 2026-07-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 83 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
MYRIAD GENETICS INC
Report date December 05, 2019 · Filed December 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,040 |
Reported balance
After 2019-12-05 transaction · row 1
1 source rowRow 1 · 2019-12-05 · Grant · Acquired 11,687 · Balance 76,040 F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 2,050 |
Reported balance
Holding disclosure · report date 2019-12-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,050 |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 14, 2020 22:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,415 | $15.43 Strike: $15.43 | $98,983.45 |
DisclosureSEC source: 0001061983-20-000030 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,415 Underlying: Common Stock · 6,415 shares Expires 2030-02-12 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,517 | $10.55 Strike: $10.55 | $16,004.35 |
DisclosureSEC source: 0001061983-20-000012 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 29, 2020 17:57 UTC Amendment | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,479 | $10.55 Strike: $10.55 | $100,003.45 |
DisclosureSEC source: 0001061983-20-000022 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,479 Underlying: Common Stock · 9,479 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. F2 · derivative.underlying_shares: This Form 4/A is being filed to report the correct number of shares underlying the stock option, which was granted to the reporting person in connection with his election to receive 100% of his non-employee director retainer in equity, pursuant to the methodology described in the Company's most recent Proxy Statement. The number of shares reported on the Form 4 filed January 6, 2020 was incorrect due to an administrative error. Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 18:14 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 11,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001226488-19-000005 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,040 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| November 19, 2019 Filed Jan 2, 2020 19:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | PurchaseCommon Stock | 6,000 | $8.57 | $51,426.60 |
DisclosureSEC source: 0001061983-20-000005 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Read SEC document |
| November 07, 2019 Filed Nov 7, 2019 18:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | PurchaseCommon Stock | 1,750 | $23.46 | $41,055.70 |
DisclosureSEC source: 0001226488-19-000003 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse Disclosed balance after: 2,050 Read SEC document |
| November 07, 2019 Filed Nov 7, 2019 18:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | PurchaseCommon Stock | 5,250 | $23.46 | $123,167.10 |
DisclosureSEC source: 0001226488-19-000003 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,353 Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $10.68 Strike: $10.68 | $213,600.00 |
DisclosureSEC source: 0001061983-19-000036 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 15, 2020 Read SEC document |
| May 15, 2019 Filed Nov 20, 2019 22:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $10.68 Strike: $10.68 | $213,600.00 |
DisclosureSEC source: 0001061983-19-000069 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 15, 2020 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,247 | $6.82 Strike: $6.82 | $56,244.54 |
DisclosureSEC source: 0001061983-19-000006 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,247 Underlying: Common Stock · 8,247 shares Expires 2029-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2020. Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 17:41 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 9,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001226488-18-000004 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,103 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.39 | $0.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · derivative · entry 10 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.39 | $0.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · derivative · entry 9 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2018-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.39 | $0.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · derivative · entry 8 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2018-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,000 | $40.17 | $401,700.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · nonDerivative · entry 6 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,743 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 10,000 | $24.39 | $243,900.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · nonDerivative · entry 5 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,000 | $42.01 | $420,085.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · nonDerivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,743 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 10,000 | $24.39 | $243,900.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,000 | $44.00 | $440,000.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,743 Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 20:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 10,000 | $24.39 | $243,900.00 |
DisclosureSEC source: 0001226488-18-000002 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2018 Filed May 17, 2018 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $9.45 Strike: $9.45 | $189,000.00 |
DisclosureSEC source: 0001061983-18-000027 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 16, 2019 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,428 | $3.50 Strike: $8.75 | $40,000.29 |
DisclosureSEC source: 0001061983-18-000002 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,428 Underlying: Common Stock · 11,428 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 11,428 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 00:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 7,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001226488-17-000007 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,743 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · derivative · entry 10 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest in full upon completion of one full year of service, generally on the earlier of the first anniversary of the date of grant or the date of the next annual meeting of stockholders. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · derivative · entry 9 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2017-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest in full upon completion of one full year of service, generally on the earlier of the first anniversary of the date of grant or the date of the next annual meeting of stockholders. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · derivative · entry 8 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2017-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest in full upon completion of one full year of service, generally on the earlier of the first anniversary of the date of grant or the date of the next annual meeting of stockholders. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,000 | $30.30 | $302,981.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · nonDerivative · entry 6 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,524 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 10,000 | $16.46 | $164,600.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · nonDerivative · entry 5 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,000 | $30.30 | $303,003.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · nonDerivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,524 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 10,000 | $16.46 | $164,600.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,000 | $30.31 | $303,056.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,524 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 18:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 10,000 | $16.46 | $164,600.00 |
DisclosureSEC source: 0001226488-17-000005 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000031 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| February 23, 2017 Filed Feb 23, 2017 16:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | PurchaseCommon Stock | 400 | $18.57 | $7,429.20 |
DisclosureSEC source: 0001226488-17-000002 · edgardoc.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,524 Read SEC document |
| February 23, 2017 Filed Feb 23, 2017 16:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | PurchaseCommon Stock | 3,600 | $18.58 | $66,888.00 |
DisclosureSEC source: 0001226488-17-000002 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,124 Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 16:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | PurchaseCommon Stock | 2,000 | $18.81 | $37,613.00 |
DisclosureSEC source: 0001226488-17-000002 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,524 Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,064 | $4.96 Strike: $12.40 | $39,999.86 |
DisclosureSEC source: 0001061983-17-000006 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,064 Underlying: Common Stock · 8,064 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 8,064 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 00:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001226488-16-000006 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,524 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2010 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 14:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,007 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001226488-16-000004 · edgardoc.xml · derivative · entry 7 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,007 shares Expires 2016-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One third vests annually beginning on the 1st anniversary of the option date. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 14:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 2,007 | $20.21 | $40,567.89 |
DisclosureSEC source: 0001226488-16-000004 · edgardoc.xml · nonDerivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 14:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 2,007 | $10.60 | $21,274.20 |
DisclosureSEC source: 0001226488-16-000004 · edgardoc.xml · nonDerivative · entry 3 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 14:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,993 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001226488-16-000004 · edgardoc.xml · derivative · entry 6 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,007 Underlying: Common Stock · 27,993 shares Expires 2016-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One third vests annually beginning on the 1st anniversary of the option date. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 14:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 27,993 | $20.51 | $574,248.40 |
DisclosureSEC source: 0001226488-16-000004 · edgardoc.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 14:38 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 27,993 | $10.60 | $296,725.80 |
DisclosureSEC source: 0001226488-16-000004 · edgardoc.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.